Title |
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma
|
---|---|
Published in |
Cochrane database of systematic reviews, February 2013
|
DOI | 10.1002/14651858.cd006246.pub2 |
Pubmed ID | |
Authors |
T S Shylasree, Andrew Bryant, Ram Athavale |
Abstract |
Ovarian carcinosarcoma, also known as malignant mixed Mullerian tumour, is a rare malignant gynaecological tumour constituting about 1% or less of all ovarian cancers. In over 80% of cases, there is extra-ovarian intra-abdominal spread at diagnosis. The primary treatment has traditionally been surgical cytoreduction followed by radiotherapy and chemotherapy or chemotherapy alone. Regimes have included cisplatin alone; a combination of doxorubicin, ifosfamide, dacarbazine, cyclophosphamide, taxol; and various other combinations. The effectiveness of these various regimens appears to be mixed. Therefore, there is a need to clarify if there is an optimum neoadjuvant or adjuvant therapy after surgical cytoreduction for this rare tumour. Also, it is important to address quality of life (QoL) issues related to treatment, particularly toxicity, as the overall prognosis appears to be poor. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 128 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 14 | 11% |
Student > Bachelor | 11 | 9% |
Student > Doctoral Student | 11 | 9% |
Unspecified | 9 | 7% |
Researcher | 9 | 7% |
Other | 27 | 21% |
Unknown | 47 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 34% |
Unspecified | 9 | 7% |
Nursing and Health Professions | 9 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Psychology | 4 | 3% |
Other | 11 | 9% |
Unknown | 46 | 36% |